At a glance
ClinicalIndex Comparison RecordN/ACompleted· 520 enrolled
Drug / intervention
Sunitinib malate +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Post Marketing Surveillance Study To Observe Safety And Efficacy Of Sutene
In Brief
An observational study evaluating Sunitinib malate and sunitinib malate for Gastrointestinal Stromal Tumors. Completed, enrolled 520 participants across 47 sites.
Detailed Summary
To monitor use in real practice including adverse events and efficacy on Sutent capsules (Sunitinib malate)
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsGastrointestinal Stromal Tumors
CountriesSouth Korea
Collaborators--
Timeline
N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 2007
Enrollment StartMay 2007
Primary CompletionMar 2015
TodayJul 2026
First PostedMar 8, 2007
Enrollment StartMay 1, 2007
Primary CompletionMar 1, 2015
TodayJul 2, 2026
Enrollment to primary: 7.8 yearsPosted 19.3 years ago
Interventions
Sunitinib malatedrug
Sunitinib : dosing not pre-determined
Sunitinib malatedrug
Sunitinib : dosing not pre-determined
sunitinib malatedrug
Sunitinib : dosing not pre-determined